Actionable traits will guide gastroenterologists in treatment of obesity

After weight is reduced, “we abandon patients as a matter of routine,” said Dr. Kaplan, noting that this is not the case in other serious chronic diseases. This is one aspect of obesity care that “we must change.”

Dr. Kaplan receives consulting fees from Eisai, Ethicon, GI Dynamics, Novo Nordisk, and Vivus, and has an ownership interest in GI Dynamics. Dr. Fanelli is a part owner of Allurion Technologies, a company that manufacturers an intragastric balloon for weight loss, and an advisor to EndoGastric Solutions. Dr. Streett and Dr. Reavis reported no relevant financial disclosures.